KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 51,679,622
- Total 13F shares
- 48,235,227
- Share change
- +1,235,072
- Total reported value
- $568,211,775
- Put/Call ratio
- 121%
- Price per share
- $11.78
- Number of holders
- 118
- Value change
- +$14,329,598
- Number of buys
- 62
- Number of sells
- 59
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
12%
|
6,249,731
|
$74,121,810 | — | 31 Mar 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.1%
|
4,192,005
|
$49,717,179 | — | 31 Mar 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
8%
|
4,125,345
|
$48,926,592 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
7.1%
|
3,687,867
|
$43,738,103 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
5%
|
2,575,000
|
$30,539,500 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
4.7%
|
2,432,234
|
$28,846,295 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
1,685,113
|
$19,985,440 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
3.1%
|
1,590,000
|
$18,857,400 | — | 31 Mar 2024 | |
| Capital World Investors |
13F
|
Company |
2.8%
|
1,464,606
|
$17,370,227 | — | 31 Mar 2024 | |
| Saturn V Capital Management LP |
13F
|
Company |
2.8%
|
1,441,952
|
$17,101,551 | — | 31 Mar 2024 | |
| First Turn Management, LLC |
13F
|
Company |
2.3%
|
1,179,420
|
$13,987,921 | — | 31 Mar 2024 | |
| TCG Crossover Management, LLC |
13F
|
Company |
2.3%
|
1,163,356
|
$13,797,402 | — | 31 Mar 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
2.2%
|
1,161,060
|
$13,770,172 | — | 31 Mar 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.6%
|
806,973
|
$9,570,700 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
1.5%
|
760,722
|
$9,022,163 | — | 31 Mar 2024 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
1.3%
|
671,176
|
$7,960,147 | — | 31 Mar 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.3%
|
655,000
|
$7,768,300 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
651,888
|
$7,732,144 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.2%
|
628,887
|
$7,458,600 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.1%
|
594,173
|
$7,046,892 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.1%
|
579,659
|
$6,874,756 | — | 31 Mar 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
561,183
|
$6,655,630 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1%
|
541,538
|
$6,422,641 | — | 31 Mar 2024 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1%
|
529,365
|
$6,278,269 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
0.97%
|
500,000
|
$5,930,000 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.82%
|
424,434
|
$5,033,787 | — | 31 Mar 2024 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.75%
|
386,000
|
$4,577,960 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.68%
|
350,000
|
$4,151,000 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.67%
|
344,449
|
$4,085,165 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.62%
|
317,868
|
$3,769,914 | — | 31 Mar 2024 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.56%
|
287,985
|
$3,415,502 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.55%
|
282,883
|
$3,354,993 | — | 31 Mar 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.49%
|
254,774
|
$3,021,620 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.47%
|
243,484
|
$2,888,000 | — | 31 Mar 2024 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.42%
|
219,277
|
$2,600,625 | — | 31 Mar 2024 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.39%
|
200,000
|
$2,372,000 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.37%
|
191,699
|
$2,273,550 | — | 31 Mar 2024 | |
| Nicholas Investment Partners, LP |
13F
|
Company |
0.35%
|
182,644
|
$2,166,158 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.35%
|
178,738
|
$2,119,833 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.29%
|
150,462
|
$1,784,479 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.28%
|
146,322
|
$1,735,379 | — | 31 Mar 2024 | |
| AlphaCentric Advisors LLC |
13F
|
Company |
0.25%
|
130,000
|
$1,541,800 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.23%
|
120,308
|
$1,426,853 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
112,053
|
$1,328,949 | — | 31 Mar 2024 | |
| Edward P. Feener |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
102,024
mixed-class rows
|
$1,200,262 | — | 17 May 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.18%
|
90,560
|
$1,074,042 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.17%
|
87,093
|
$1,032,923 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.17%
|
87,084
|
$1,032,816 | — | 31 Mar 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.16%
|
82,000
|
$972,520 | — | 31 Mar 2024 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q2 2024
As of 30 Jun 2024,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
118 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,235,227 shares.
The largest 10 holders included
VR Adviser, LLC, TANG CAPITAL MANAGEMENT LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., Capital World Investors, BlackRock Inc., Vestal Point Capital, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, and Boxer Capital, LLC.
This page lists
118
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
128
Q2 2024 holders
118
Holder diff
-10
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.